StemoniX Revenue and Competitors
Estimated Revenue & Valuation
- StemoniX's estimated annual revenue is currently $77.5k per year.
- StemoniX's estimated revenue per employee is $77,500
- StemoniX's total funding is $37.6M.
Employee Data
- StemoniX has 1 Employees.
- StemoniX grew their employee count by -86% last year.
StemoniX's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CFO | Reveal Email/Phone |
2 | Director Operations | Reveal Email/Phone |
3 | Sales Operations Manager & Marketing Communications at StemoniX | Reveal Email/Phone |
StemoniX Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $7.8M | 50 | 9% | N/A | N/A |
#2 | $7.4M | 48 | -35% | N/A | N/A |
#3 | $0.9M | 6 | 20% | N/A | N/A |
#4 | $0.3M | 2 | -91% | N/A | N/A |
#5 | $3.6M | 23 | 5% | N/A | N/A |
#6 | $0.9M | 6 | -33% | N/A | N/A |
#7 | $5M | 32 | 3% | N/A | N/A |
#8 | $14.7M | 95 | 9% | N/A | N/A |
#9 | $14.7M | 95 | 0% | $20.5M | N/A |
#10 | $27.9M | 144 | 13% | $39.1M | N/A |
What Is StemoniX?
Our mission is to accelerate the discovery of new medicines with physiologically-relevant, structured human cells that improve cell-based assay outcomes. We develop and scalably manufacture human induced pluripotent stem (iPS) cell-derived cardiac and neuronal platforms for drug discovery and development. Predictive, accurate, and consistent, our human models enable scientists to quickly and economically conduct research with improved outcomes in a simplified workflow. We also collaborate with drug discovery organizations to test their compounds with our in-house screening capabilities, create new cell-based models, and operationalize their human iPS cells at large scale for high throughput screening. StemoniX microHeart® products in high density plate formats provide researchers with structurally aligned cardiac cells resembling native human heart tissue with accelerated features of cell maturity. StemoniX microBrain® products in high density formats are physiologically relevant with biology, activity, functional maturity that mimic native human brain tissue. Available pre-plated to simplify your workflow, microHeart and microBrain are delivered in ambient conditions and ready for assay use soon after delivery. With leading-edge iPSC technologies, we are helping global institutions bring the most promising medicines to patients. Contact us at info@stemonix.com to discuss how StemoniX products and services can accelerate your discoveries.
keywords:N/A
$37.6M
Total Funding
1
Number of Employees
$77.5k
Revenue (est)
-86%
Employee Growth %
N/A
Valuation
N/A
Accelerator
StemoniX News
StemoniX is empowering the discovery of new medicines through the convergence of novel human biology and software technologies. vivoPharm offers...
Maple Grove, Minnesota--(Newsfile Corp. - January 11, 2021) - StemoniX, a biotech company changing how new drugs are discovered, announced today their participation at the 2021 Biotech Showcase™ being held January 11-15th as part of OrganAi, a joint venture between StemoniX and Atomwise. The com ...
Other Companies in Minneapolis
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.1M | 1 | -75% | N/A |
#2 | $0.1M | 1 | 0% | N/A |
#3 | $0.1M | 1 | -50% | N/A |
#4 | $0.1M | 1 | 0% | N/A |
#5 | $0.1M | 1 | 0% | N/A |